BC
ANAB icon

Bridgefront Capital’s AnaptysBio ANAB Stock Holding History

Bridgefront Capital’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,549
Closed -$414K – 520
2025
Q4 		$414K Buy
+8,549
New +$333K 0.1% 313
2025
Q1 		– Sell
-19,011
Closed -$252K – 609
2024
Q4 		$252K Buy
+19,011
New +$461K 0.08% 418

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Bridgefront Capital's ANAB Position: Q1 2026 in Review

Bridgefront Capital sold out of AnaptysBio (ANAB) in Q1 2026, closing a stake of 8,549 shares — an estimated $414K sold.

Bridgefront Capital first reported a position in ANAB in Q4 2024 and held it in 2 quarters. The position peaked at $414K in Q4 2025. 208 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Bridgefront Capital reported no remaining AnaptysBio position as of Q1 2026 after selling out during the quarter.
  • Bridgefront Capital sold 8,549 AnaptysBio shares in Q1 2026, an estimated $414K.
  • Bridgefront Capital first reported a position in AnaptysBio in Q4 2024 and held it in 2 quarters.
  • Bridgefront Capital's AnaptysBio position peaked at $414K in Q4 2025.
  • 208 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.